VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research note published on Sunday. The firm issued a sell rating on the stock.

VNRX has been the topic of several other research reports. HC Wainwright initiated coverage on shares of VolitionRx in a report on Tuesday, April 8th. They issued a “buy” rating and a $2.50 target price on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a report on Monday, March 31st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.33.

VolitionRx Stock Performance

VNRX opened at $0.49 on Friday. The company’s 50-day simple moving average is $0.56 and its two-hundred day simple moving average is $0.62. VolitionRx has a 52-week low of $0.42 and a 52-week high of $1.02. The stock has a market capitalization of $49.06 million, a P/E ratio of -1.35 and a beta of 1.15.

Insider Transactions at VolitionRx

In related news, CEO Cameron John Reynolds purchased 181,818 shares of VolitionRx stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $0.55 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief executive officer now directly owns 2,299,222 shares in the company, valued at $1,264,572.10. This represents a 8.59 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in VNRX. Geode Capital Management LLC lifted its holdings in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after purchasing an additional 95,900 shares in the last quarter. Millennium Management LLC bought a new stake in shares of VolitionRx during the 4th quarter valued at $36,000. Lagoda Investment Management L.P. lifted its stake in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after buying an additional 1,481,000 shares in the last quarter. Northern Trust Corp boosted its holdings in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares during the period. Finally, Two Sigma Securities LLC bought a new stake in VolitionRx during the fourth quarter valued at about $29,000. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.